4.890USDMkt Cap: 176.12M USDP/E: —Last update: 2026-05-21
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a on…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap176.12M USD
Enterprise Value90.83M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-35.17M USD
Revenue/Share—
Last Price4.890 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.70
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.15
EPS (TTM)-1.10
EPS (Forward)-1.04
52W Range
4.56092% of range4.920
52W High4.920 USD
52W Low4.560 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.29%
ROA-56.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.83M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-10.85%
Net Debt-85.29M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio15.73
Quick Ratio15.33
Book Value/Sh2.272 USD
Cash/Share2.368 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)9.000 USD
Target Range9.000 USD – 9.000 USD
# Analysts1
Ownership
Shares Out.36.02M
Float17.02M
Insiders18.87%
Institutions70.48%
Short Interest
Short Ratio2.6d
Short % Float2.93%
Short % Out.2.44%
Shares Short879.49K
Short (prev mo.)564.27K
Technical
SMA 504.094 (+19.4%)
SMA 2001.968 (+148.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)101.83K
Avg Vol (10d)200.07K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—